Atrial natriuretic peptide augments the variability of sympathetic nerve activity in human heart failure

Activation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within the low frequency (LF, 0.05-0.15 Hz) range are three adverse features of advanced congestive heart failure (CHF). In healthy men, atrial nat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hypertension Vol. 19; no. 3 Pt 2; p. 619
Main Authors: Kubo, T, Ando, S, Picton, P, Atchison, D J, Notarius, C F, Pollard, M J, Abramson, B L, Floras, J S
Format: Journal Article
Language:English
Published: England 01.03.2001
Subjects:
ISSN:0263-6352
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Activation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within the low frequency (LF, 0.05-0.15 Hz) range are three adverse features of advanced congestive heart failure (CHF). In healthy men, atrial natriuretic peptide (ANP) infusion attenuates reflex increases in MSNA and reduces LF components of HRV spectral power. Sympathoinhibitory actions have also been documented in CHF, but effects on the variability of MSNA and HRV have not been described. Heart rate and MSNA were recorded in 10 men (aged 39 +/- 3 years, mean +/- SE) with dilated cardiomyopathy (mean EF 20 +/- 4%) treated with angiotensin converting enzyme (ACE) inhibitors. Subjects received i.v. ANP (50 microg bolus then 50 ng/kg/min) and nitroglycerin (NTG, 8 mg/min) as a hemodynamic control. Signals at baseline, and 13-20 min into each infusion were submitted to spectral analysis. ANP had no effect on HRV, but increased MSNA LF (from 7.9 +/- 1.5 to 12.1 +/- 2.6 U2; P< 0.02) and total spectral power (from 47.9 +/- 5.4 to 61.9 +/- 6.8 U2; P < 0.05). NTG had no effect on the variability of MSNA or HRV. In CHF patients receiving ACE inhibitors, ANP (i) does not suppress HRV and (ii) enhances the modulation of MSNA, particularly within the LF range. This latter action is not observed with NTG. These findings suggest beneficial actions of exogenous ANP on neurogenic circulatory control.
AbstractList Activation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within the low frequency (LF, 0.05-0.15 Hz) range are three adverse features of advanced congestive heart failure (CHF). In healthy men, atrial natriuretic peptide (ANP) infusion attenuates reflex increases in MSNA and reduces LF components of HRV spectral power. Sympathoinhibitory actions have also been documented in CHF, but effects on the variability of MSNA and HRV have not been described. Heart rate and MSNA were recorded in 10 men (aged 39 +/- 3 years, mean +/- SE) with dilated cardiomyopathy (mean EF 20 +/- 4%) treated with angiotensin converting enzyme (ACE) inhibitors. Subjects received i.v. ANP (50 microg bolus then 50 ng/kg/min) and nitroglycerin (NTG, 8 mg/min) as a hemodynamic control. Signals at baseline, and 13-20 min into each infusion were submitted to spectral analysis. ANP had no effect on HRV, but increased MSNA LF (from 7.9 +/- 1.5 to 12.1 +/- 2.6 U2; P< 0.02) and total spectral power (from 47.9 +/- 5.4 to 61.9 +/- 6.8 U2; P < 0.05). NTG had no effect on the variability of MSNA or HRV. In CHF patients receiving ACE inhibitors, ANP (i) does not suppress HRV and (ii) enhances the modulation of MSNA, particularly within the LF range. This latter action is not observed with NTG. These findings suggest beneficial actions of exogenous ANP on neurogenic circulatory control.
Activation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within the low frequency (LF, 0.05-0.15 Hz) range are three adverse features of advanced congestive heart failure (CHF). In healthy men, atrial natriuretic peptide (ANP) infusion attenuates reflex increases in MSNA and reduces LF components of HRV spectral power. Sympathoinhibitory actions have also been documented in CHF, but effects on the variability of MSNA and HRV have not been described.OBJECTIVESActivation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within the low frequency (LF, 0.05-0.15 Hz) range are three adverse features of advanced congestive heart failure (CHF). In healthy men, atrial natriuretic peptide (ANP) infusion attenuates reflex increases in MSNA and reduces LF components of HRV spectral power. Sympathoinhibitory actions have also been documented in CHF, but effects on the variability of MSNA and HRV have not been described.Heart rate and MSNA were recorded in 10 men (aged 39 +/- 3 years, mean +/- SE) with dilated cardiomyopathy (mean EF 20 +/- 4%) treated with angiotensin converting enzyme (ACE) inhibitors. Subjects received i.v. ANP (50 microg bolus then 50 ng/kg/min) and nitroglycerin (NTG, 8 mg/min) as a hemodynamic control. Signals at baseline, and 13-20 min into each infusion were submitted to spectral analysis.DESIGN AND METHODSHeart rate and MSNA were recorded in 10 men (aged 39 +/- 3 years, mean +/- SE) with dilated cardiomyopathy (mean EF 20 +/- 4%) treated with angiotensin converting enzyme (ACE) inhibitors. Subjects received i.v. ANP (50 microg bolus then 50 ng/kg/min) and nitroglycerin (NTG, 8 mg/min) as a hemodynamic control. Signals at baseline, and 13-20 min into each infusion were submitted to spectral analysis.ANP had no effect on HRV, but increased MSNA LF (from 7.9 +/- 1.5 to 12.1 +/- 2.6 U2; P< 0.02) and total spectral power (from 47.9 +/- 5.4 to 61.9 +/- 6.8 U2; P < 0.05). NTG had no effect on the variability of MSNA or HRV.RESULTSANP had no effect on HRV, but increased MSNA LF (from 7.9 +/- 1.5 to 12.1 +/- 2.6 U2; P< 0.02) and total spectral power (from 47.9 +/- 5.4 to 61.9 +/- 6.8 U2; P < 0.05). NTG had no effect on the variability of MSNA or HRV.In CHF patients receiving ACE inhibitors, ANP (i) does not suppress HRV and (ii) enhances the modulation of MSNA, particularly within the LF range. This latter action is not observed with NTG. These findings suggest beneficial actions of exogenous ANP on neurogenic circulatory control.CONCLUSIONSIn CHF patients receiving ACE inhibitors, ANP (i) does not suppress HRV and (ii) enhances the modulation of MSNA, particularly within the LF range. This latter action is not observed with NTG. These findings suggest beneficial actions of exogenous ANP on neurogenic circulatory control.
Author Floras, J S
Abramson, B L
Ando, S
Kubo, T
Picton, P
Notarius, C F
Atchison, D J
Pollard, M J
Author_xml – sequence: 1
  givenname: T
  surname: Kubo
  fullname: Kubo, T
  organization: Division of Cardiology of the Toronto General and Mount Sinai Hospitals, University of Toronto, Canada
– sequence: 2
  givenname: S
  surname: Ando
  fullname: Ando, S
– sequence: 3
  givenname: P
  surname: Picton
  fullname: Picton, P
– sequence: 4
  givenname: D J
  surname: Atchison
  fullname: Atchison, D J
– sequence: 5
  givenname: C F
  surname: Notarius
  fullname: Notarius, C F
– sequence: 6
  givenname: M J
  surname: Pollard
  fullname: Pollard, M J
– sequence: 7
  givenname: B L
  surname: Abramson
  fullname: Abramson, B L
– sequence: 8
  givenname: J S
  surname: Floras
  fullname: Floras, J S
BackLink https://www.ncbi.nlm.nih.gov/pubmed/11327638$$D View this record in MEDLINE/PubMed
BookMark eNo1kMtOwzAURL0oog_4BeQVu4AfcWwvq4qXVIkNrKNb26FGiRNip1L-HleUu5iR5h7NYtZoEfrgEMKUPFCi5SPJVyrJCkYIJTxLkRMqFmhFWMWLigu2ROsYv3OstOTXaEkpZ7LiaoWO2zR6aHGA7NPokjd4cEPy1mGYvjoXUsTp6PAJMnfwrU8z7hsc526AnJ_54MZTpk3yp_PXB3ycOsjqYEy4Ad_m4ht01UAb3e3FN-jz-elj91rs31_edtt9YUpBRNGIRkKlrWGGWakIZRKUcIQzqqkEqyQVoIw2ZamFtdpWiiuphdC0ASYqtkH3f73D2P9MLqa689G4toXg-inWkigiteYZvLuA06Fzth5G38E41__bsF8zMWho
CitedBy_id crossref_primary_10_1152_japplphysiol_00027_2002
crossref_primary_10_1097_HJH_0000000000000575
crossref_primary_10_1016_j_autneu_2021_102834
crossref_primary_10_1016_S0167_5273_02_00308_X
crossref_primary_10_1097_HJH_0000000000002093
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1097/00004872-200103001-00015
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 11327638
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.-D
.55
.GJ
.XZ
.Z2
01R
0R~
1J1
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AAUEB
AAWTL
AAXQO
AAYEP
ABASU
ABBUW
ABDIG
ABJNI
ABOCM
ABVCZ
ABXVJ
ABZAD
ACCJW
ACDDN
ACEWG
ACGFO
ACGFS
ACIJW
ACILI
ACLDA
ACWDW
ACWRI
ACXJB
ACXNZ
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEBDS
AEETU
AENEX
AFDTB
AFEXH
AFFNX
AFSOK
AFUWQ
AGINI
AHOMT
AHQNM
AHRYX
AHVBC
AI.
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
BOYCO
BQLVK
BS7
C45
CAG
CGR
COF
CS3
CUY
CVF
DIWNM
DU5
DUNZO
E.X
EBS
ECM
EEVPB
EIF
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FW0
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
JF9
JG8
JK3
JK8
K8S
KD2
KMI
L-C
L7B
N9A
NPM
N~7
N~B
N~M
O9-
OAG
OAH
OCUKA
ODA
ODMTH
OHYEH
OJAPA
OL1
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
R58
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VH1
VVN
W3M
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YYP
ZFV
ZGI
ZXP
ZZMQN
7X8
ABPXF
ACDOF
ACZKN
ADKSD
AFNMH
ID FETCH-LOGICAL-c4505-f5f7a69dc2c2d780127a85e0321917ad8715a8c9c4495dd9d6838795591fa2562
IEDL.DBID 7X8
ISICitedReferencesCount 8
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00004872-200103001-00015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0263-6352
IngestDate Sun Sep 28 09:39:02 EDT 2025
Wed Feb 19 02:34:06 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3 Pt 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4505-f5f7a69dc2c2d780127a85e0321917ad8715a8c9c4495dd9d6838795591fa2562
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 11327638
PQID 70807993
PQPubID 23479
ParticipantIDs proquest_miscellaneous_70807993
pubmed_primary_11327638
PublicationCentury 2000
PublicationDate 2001-March
PublicationDateYYYYMMDD 2001-03-01
PublicationDate_xml – month: 03
  year: 2001
  text: 2001-March
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of hypertension
PublicationTitleAlternate J Hypertens
PublicationYear 2001
SSID ssj0008973
Score 1.666456
Snippet Activation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 619
SubjectTerms Adult
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Atrial Natriuretic Factor - pharmacology
Cardiac Output, Low - physiopathology
Cardiomyopathy, Dilated - drug therapy
Cardiomyopathy, Dilated - physiopathology
Heart Rate - drug effects
Humans
Male
Middle Aged
Nitroglycerin - therapeutic use
Sympathetic Nervous System - drug effects
Sympathetic Nervous System - physiopathology
Vasodilator Agents - therapeutic use
Title Atrial natriuretic peptide augments the variability of sympathetic nerve activity in human heart failure
URI https://www.ncbi.nlm.nih.gov/pubmed/11327638
https://www.proquest.com/docview/70807993
Volume 19
WOSCitedRecordID wos00004872-200103001-00015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELYKRYiF96M8PbBaNHYcxxISQoiKpVUHkLpVrh_QgaTQh9R_z53TqBNiYMmURJF9vvsu9919hNyK1AhpU8UgF5As5WoEfjAYZlxuM5ekibPtKDaher18MND9Brmve2GQVln7xOioXWnxH_mdAmijIJg-TL4YakZhbXUloLFBmgKADNq0Gqxnhee6qi_zTDAIqzWPpx7ZCEido42gzham1IgefoeZMdx09v73oftkdwUz6WNlFwek4YtDst1dFdKPyMdjlOugBU7on8dORjpBgovz1MzfY98bBWxIF5BLV6O8l7QMdLr8RA3jeH-BZEmKjRGoP0HHBY2CfxQ1smc0mDEy3o_JW-f59emFrUQXmE0BDbEggzKZdpZb7hTGL2Vy6duCY2YHW6gSaXKrbQqplXPaZblAwXKpk2AAP_ETslmUhT8j1BkRjFQ6sYAhnM5G8G4t2s4L4_lIyBa5qVdwCEaNlQpT-HI-HdZr2CKn1SYMJ9XsDUhYBAeXmJ__-ewF2VnzxS5JM8Bx9ldkyy5m4-n3dbQVuPb63R_pmchV
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Atrial+natriuretic+peptide+augments+the+variability+of+sympathetic+nerve+activity+in+human+heart+failure&rft.jtitle=Journal+of+hypertension&rft.au=Kubo%2C+T&rft.au=Ando%2C+S&rft.au=Picton%2C+P&rft.au=Atchison%2C+D+J&rft.date=2001-03-01&rft.issn=0263-6352&rft.volume=19&rft.issue=3+Pt+2&rft.spage=619&rft_id=info:doi/10.1097%2F00004872-200103001-00015&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0263-6352&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0263-6352&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0263-6352&client=summon